Global Rapid Adenovirus Testing Market

Rapid Adenovirus Testing Comprehensive Study by Application (Hospitals, Clinics, Others), Assay (Lateral Flow Immunochromatographic Assay, Immunogold Assay, PCR-Enzyme Hybridization Assay), Diagnosis (Antigen Detection, Polymerase Chain Reaction (PCR), Virus Isolation, Monoclonal Antibodies, Liposomes and Flow Cytometry, Chromatography, Gel Microdroplets) Players and Region - Global Market Outlook to 2027

Rapid Adenovirus Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Rapid Adenovirus Testing
Adenovirus is linked to a wide range of non-specific symptoms or clinical syndromes, making it difficult to identify based only on clinical criteria. When the infection displays indications of an epidemic or when the individual shows symptoms of a serious disease, the diagnosis is the most accurate. Rapid detection and quantification of viral DNA using highly sensitive PCR methods could be beneficial for adenovirus infection diagnosis and therapy monitoring, especially in immunocompromised individuals.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The Rapid Adenovirus Testing players are exploring the market by adopting mergers & acquisitions, expansions, investments, new product launches, and collaborations as their preferred strategies. Several companies have to launch methods of Rapid Adenovirus Testing for early detection of disease and can act as a lifesaving step. These adoptions make companies remain competitive in the market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Rapid Adenovirus Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Biopanda Reagents Ltd (United Kingdom), CTK Biotech Inc. (United States), Creative Diagnostics (United States), Intec Products Inc. (China), Biomérieux India Private Limited, Accuquik (United States), SA Scientific (United States), F. Hoffmann-La Roche Ltd (Switzerland), Diasorin S.P.A (Italy), Bio-Rad Laboratories Inc. (United States) and Qiagen (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Rapid Adenovirus Testing market by , Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of Rapid Adenovirus Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Assay, the sub-segment i.e. Lateral Flow Immunochromatographic Assay will boost the Rapid Adenovirus Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Antigen Detection will boost the Rapid Adenovirus Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

On 01 April 2020, Otsuka launch the adenovirus test kit QuickNavi. The QuickNaviTM-Adeno2 is a testing kit that enhances the use and performance of the QuickNavi-Adeno, allowing for faster and more accurate detection of adenovirus infection. QuickNavi-Adeno2 is an immunochromatography-based measuring kit for detecting viral antigens in pharyngeal swabs, keratoconjunctival wipes, nasal swabs, and nasal aspirates.
“As per Centers for Disease Control and Prevention (CDC) Antigen detection, polymerase chain reaction (PCR), viral isolation, and serology can all be used to diagnose adenovirus infections. Molecular techniques are commonly used to type adenoviruses. Health care professionals should carefully implement infection control procedures to avoid healthcare-associated epidemics of adenovirus infections, such as epidemic keratoconjunctivitis. Adenoviruses are resistant to a variety of popular disinfectants and can survive for long periods of time on surfaces in the environment and on medical devices.”

Market Drivers
  • Need to Control the Infection Caused by Adenovirus
  • Increased Investment in Research and Development and Technological

Opportunities
  • Advancement in the Diagnosis of Acute Respiratory Infections of Adenovirus

Restraints
  • Lack of Awareness Associated with Rapid Adenovirus Testing

Challenges
  • Lack of Trained Technicians in Developing Countries


Key Target Audience
Rapid Adenovirus Testing Manufacturer, Rapid Adenovirus Testing Association, Testing Laboratories, Research and Development Institutes, Financial Institutes and Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Others
By Assay
  • Lateral Flow Immunochromatographic Assay
  • Immunogold Assay
  • PCR-Enzyme Hybridization Assay

By Diagnosis
  • Antigen Detection
  • Polymerase Chain Reaction (PCR)
  • Virus Isolation
  • Monoclonal Antibodies
  • Liposomes and Flow Cytometry
  • Chromatography
  • Gel Microdroplets

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Need to Control the Infection Caused by Adenovirus
      • 3.2.2. Increased Investment in Research and Development and Technological
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Technicians in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Advancement of Different PCR Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rapid Adenovirus Testing, by Application, Assay, Diagnosis and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Rapid Adenovirus Testing (Value)
      • 5.2.1. Global Rapid Adenovirus Testing by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Rapid Adenovirus Testing by: Assay (Value)
        • 5.2.2.1. Lateral Flow Immunochromatographic Assay
        • 5.2.2.2. Immunogold Assay
        • 5.2.2.3. PCR-Enzyme Hybridization Assay
      • 5.2.3. Global Rapid Adenovirus Testing by: Diagnosis (Value)
        • 5.2.3.1. Antigen Detection
        • 5.2.3.2. Polymerase Chain Reaction (PCR)
        • 5.2.3.3. Virus Isolation
        • 5.2.3.4. Monoclonal Antibodies
        • 5.2.3.5. Liposomes and Flow Cytometry
        • 5.2.3.6. Chromatography
        • 5.2.3.7. Gel Microdroplets
      • 5.2.4. Global Rapid Adenovirus Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Rapid Adenovirus Testing (Volume)
      • 5.3.1. Global Rapid Adenovirus Testing by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Rapid Adenovirus Testing by: Assay (Volume)
        • 5.3.2.1. Lateral Flow Immunochromatographic Assay
        • 5.3.2.2. Immunogold Assay
        • 5.3.2.3. PCR-Enzyme Hybridization Assay
      • 5.3.3. Global Rapid Adenovirus Testing by: Diagnosis (Volume)
        • 5.3.3.1. Antigen Detection
        • 5.3.3.2. Polymerase Chain Reaction (PCR)
        • 5.3.3.3. Virus Isolation
        • 5.3.3.4. Monoclonal Antibodies
        • 5.3.3.5. Liposomes and Flow Cytometry
        • 5.3.3.6. Chromatography
        • 5.3.3.7. Gel Microdroplets
      • 5.3.4. Global Rapid Adenovirus Testing Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Rapid Adenovirus Testing (Price)
  • 6. Rapid Adenovirus Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biopanda Reagents Ltd (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CTK Biotech Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Creative Diagnostics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Intec Products Inc. (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biomérieux India Private Limited
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Accuquik (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SA Scientific (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Diasorin S.P.A (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bio-Rad Laboratories Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Qiagen (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Rapid Adenovirus Testing Sale, by Application, Assay, Diagnosis and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Rapid Adenovirus Testing (Value)
      • 7.2.1. Global Rapid Adenovirus Testing by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Rapid Adenovirus Testing by: Assay (Value)
        • 7.2.2.1. Lateral Flow Immunochromatographic Assay
        • 7.2.2.2. Immunogold Assay
        • 7.2.2.3. PCR-Enzyme Hybridization Assay
      • 7.2.3. Global Rapid Adenovirus Testing by: Diagnosis (Value)
        • 7.2.3.1. Antigen Detection
        • 7.2.3.2. Polymerase Chain Reaction (PCR)
        • 7.2.3.3. Virus Isolation
        • 7.2.3.4. Monoclonal Antibodies
        • 7.2.3.5. Liposomes and Flow Cytometry
        • 7.2.3.6. Chromatography
        • 7.2.3.7. Gel Microdroplets
      • 7.2.4. Global Rapid Adenovirus Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Rapid Adenovirus Testing (Volume)
      • 7.3.1. Global Rapid Adenovirus Testing by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Rapid Adenovirus Testing by: Assay (Volume)
        • 7.3.2.1. Lateral Flow Immunochromatographic Assay
        • 7.3.2.2. Immunogold Assay
        • 7.3.2.3. PCR-Enzyme Hybridization Assay
      • 7.3.3. Global Rapid Adenovirus Testing by: Diagnosis (Volume)
        • 7.3.3.1. Antigen Detection
        • 7.3.3.2. Polymerase Chain Reaction (PCR)
        • 7.3.3.3. Virus Isolation
        • 7.3.3.4. Monoclonal Antibodies
        • 7.3.3.5. Liposomes and Flow Cytometry
        • 7.3.3.6. Chromatography
        • 7.3.3.7. Gel Microdroplets
      • 7.3.4. Global Rapid Adenovirus Testing Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Rapid Adenovirus Testing (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rapid Adenovirus Testing: by Application(USD Million)
  • Table 2. Rapid Adenovirus Testing Hospitals , by Region USD Million (2016-2021)
  • Table 3. Rapid Adenovirus Testing Clinics , by Region USD Million (2016-2021)
  • Table 4. Rapid Adenovirus Testing Others , by Region USD Million (2016-2021)
  • Table 5. Rapid Adenovirus Testing: by Assay(USD Million)
  • Table 6. Rapid Adenovirus Testing Lateral Flow Immunochromatographic Assay , by Region USD Million (2016-2021)
  • Table 7. Rapid Adenovirus Testing Immunogold Assay , by Region USD Million (2016-2021)
  • Table 8. Rapid Adenovirus Testing PCR-Enzyme Hybridization Assay , by Region USD Million (2016-2021)
  • Table 9. Rapid Adenovirus Testing: by Diagnosis(USD Million)
  • Table 10. Rapid Adenovirus Testing Antigen Detection , by Region USD Million (2016-2021)
  • Table 11. Rapid Adenovirus Testing Polymerase Chain Reaction (PCR) , by Region USD Million (2016-2021)
  • Table 12. Rapid Adenovirus Testing Virus Isolation , by Region USD Million (2016-2021)
  • Table 13. Rapid Adenovirus Testing Monoclonal Antibodies , by Region USD Million (2016-2021)
  • Table 14. Rapid Adenovirus Testing Liposomes and Flow Cytometry , by Region USD Million (2016-2021)
  • Table 15. Rapid Adenovirus Testing Chromatography , by Region USD Million (2016-2021)
  • Table 16. Rapid Adenovirus Testing Gel Microdroplets , by Region USD Million (2016-2021)
  • Table 17. South America Rapid Adenovirus Testing, by Country USD Million (2016-2021)
  • Table 18. South America Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 19. South America Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 20. South America Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 21. Brazil Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 22. Brazil Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 23. Brazil Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 24. Argentina Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 25. Argentina Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 26. Argentina Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 27. Rest of South America Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 28. Rest of South America Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 29. Rest of South America Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 30. Asia Pacific Rapid Adenovirus Testing, by Country USD Million (2016-2021)
  • Table 31. Asia Pacific Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 32. Asia Pacific Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 33. Asia Pacific Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 34. China Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 35. China Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 36. China Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 37. Japan Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 38. Japan Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 39. Japan Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 40. India Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 41. India Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 42. India Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 43. South Korea Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 44. South Korea Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 45. South Korea Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 46. Taiwan Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 47. Taiwan Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 48. Taiwan Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 49. Australia Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 50. Australia Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 51. Australia Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 55. Europe Rapid Adenovirus Testing, by Country USD Million (2016-2021)
  • Table 56. Europe Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 57. Europe Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 58. Europe Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 59. Germany Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 60. Germany Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 61. Germany Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 62. France Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 63. France Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 64. France Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 65. Italy Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 66. Italy Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 67. Italy Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 68. United Kingdom Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 69. United Kingdom Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 70. United Kingdom Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 71. Netherlands Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 72. Netherlands Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 73. Netherlands Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 74. Rest of Europe Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 75. Rest of Europe Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 76. Rest of Europe Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 77. MEA Rapid Adenovirus Testing, by Country USD Million (2016-2021)
  • Table 78. MEA Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 79. MEA Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 80. MEA Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 81. Middle East Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 82. Middle East Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 83. Middle East Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 84. Africa Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 85. Africa Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 86. Africa Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 87. North America Rapid Adenovirus Testing, by Country USD Million (2016-2021)
  • Table 88. North America Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 89. North America Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 90. North America Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 91. United States Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 92. United States Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 93. United States Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 94. Canada Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 95. Canada Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 96. Canada Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 97. Mexico Rapid Adenovirus Testing, by Application USD Million (2016-2021)
  • Table 98. Mexico Rapid Adenovirus Testing, by Assay USD Million (2016-2021)
  • Table 99. Mexico Rapid Adenovirus Testing, by Diagnosis USD Million (2016-2021)
  • Table 100. Rapid Adenovirus Testing Sales: by Application(K Units)
  • Table 101. Rapid Adenovirus Testing Sales Hospitals , by Region K Units (2016-2021)
  • Table 102. Rapid Adenovirus Testing Sales Clinics , by Region K Units (2016-2021)
  • Table 103. Rapid Adenovirus Testing Sales Others , by Region K Units (2016-2021)
  • Table 104. Rapid Adenovirus Testing Sales: by Assay(K Units)
  • Table 105. Rapid Adenovirus Testing Sales Lateral Flow Immunochromatographic Assay , by Region K Units (2016-2021)
  • Table 106. Rapid Adenovirus Testing Sales Immunogold Assay , by Region K Units (2016-2021)
  • Table 107. Rapid Adenovirus Testing Sales PCR-Enzyme Hybridization Assay , by Region K Units (2016-2021)
  • Table 108. Rapid Adenovirus Testing Sales: by Diagnosis(K Units)
  • Table 109. Rapid Adenovirus Testing Sales Antigen Detection , by Region K Units (2016-2021)
  • Table 110. Rapid Adenovirus Testing Sales Polymerase Chain Reaction (PCR) , by Region K Units (2016-2021)
  • Table 111. Rapid Adenovirus Testing Sales Virus Isolation , by Region K Units (2016-2021)
  • Table 112. Rapid Adenovirus Testing Sales Monoclonal Antibodies , by Region K Units (2016-2021)
  • Table 113. Rapid Adenovirus Testing Sales Liposomes and Flow Cytometry , by Region K Units (2016-2021)
  • Table 114. Rapid Adenovirus Testing Sales Chromatography , by Region K Units (2016-2021)
  • Table 115. Rapid Adenovirus Testing Sales Gel Microdroplets , by Region K Units (2016-2021)
  • Table 116. South America Rapid Adenovirus Testing Sales, by Country K Units (2016-2021)
  • Table 117. South America Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 118. South America Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 119. South America Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 120. Brazil Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 121. Brazil Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 122. Brazil Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 123. Argentina Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 124. Argentina Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 125. Argentina Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 126. Rest of South America Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 127. Rest of South America Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 128. Rest of South America Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 129. Asia Pacific Rapid Adenovirus Testing Sales, by Country K Units (2016-2021)
  • Table 130. Asia Pacific Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 131. Asia Pacific Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 132. Asia Pacific Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 133. China Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 134. China Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 135. China Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 136. Japan Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 137. Japan Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 138. Japan Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 139. India Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 140. India Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 141. India Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 142. South Korea Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 143. South Korea Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 144. South Korea Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 145. Taiwan Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 146. Taiwan Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 147. Taiwan Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 148. Australia Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 149. Australia Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 150. Australia Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 151. Rest of Asia-Pacific Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 152. Rest of Asia-Pacific Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 153. Rest of Asia-Pacific Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 154. Europe Rapid Adenovirus Testing Sales, by Country K Units (2016-2021)
  • Table 155. Europe Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 156. Europe Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 157. Europe Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 158. Germany Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 159. Germany Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 160. Germany Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 161. France Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 162. France Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 163. France Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 164. Italy Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 165. Italy Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 166. Italy Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 167. United Kingdom Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 168. United Kingdom Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 169. United Kingdom Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 170. Netherlands Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 171. Netherlands Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 172. Netherlands Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 173. Rest of Europe Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 174. Rest of Europe Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 175. Rest of Europe Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 176. MEA Rapid Adenovirus Testing Sales, by Country K Units (2016-2021)
  • Table 177. MEA Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 178. MEA Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 179. MEA Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 180. Middle East Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 181. Middle East Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 182. Middle East Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 183. Africa Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 184. Africa Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 185. Africa Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 186. North America Rapid Adenovirus Testing Sales, by Country K Units (2016-2021)
  • Table 187. North America Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 188. North America Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 189. North America Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 190. United States Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 191. United States Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 192. United States Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 193. Canada Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 194. Canada Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 195. Canada Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 196. Mexico Rapid Adenovirus Testing Sales, by Application K Units (2016-2021)
  • Table 197. Mexico Rapid Adenovirus Testing Sales, by Assay K Units (2016-2021)
  • Table 198. Mexico Rapid Adenovirus Testing Sales, by Diagnosis K Units (2016-2021)
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Rapid Adenovirus Testing: by Application(USD Million)
  • Table 211. Rapid Adenovirus Testing Hospitals , by Region USD Million (2022-2027)
  • Table 212. Rapid Adenovirus Testing Clinics , by Region USD Million (2022-2027)
  • Table 213. Rapid Adenovirus Testing Others , by Region USD Million (2022-2027)
  • Table 214. Rapid Adenovirus Testing: by Assay(USD Million)
  • Table 215. Rapid Adenovirus Testing Lateral Flow Immunochromatographic Assay , by Region USD Million (2022-2027)
  • Table 216. Rapid Adenovirus Testing Immunogold Assay , by Region USD Million (2022-2027)
  • Table 217. Rapid Adenovirus Testing PCR-Enzyme Hybridization Assay , by Region USD Million (2022-2027)
  • Table 218. Rapid Adenovirus Testing: by Diagnosis(USD Million)
  • Table 219. Rapid Adenovirus Testing Antigen Detection , by Region USD Million (2022-2027)
  • Table 220. Rapid Adenovirus Testing Polymerase Chain Reaction (PCR) , by Region USD Million (2022-2027)
  • Table 221. Rapid Adenovirus Testing Virus Isolation , by Region USD Million (2022-2027)
  • Table 222. Rapid Adenovirus Testing Monoclonal Antibodies , by Region USD Million (2022-2027)
  • Table 223. Rapid Adenovirus Testing Liposomes and Flow Cytometry , by Region USD Million (2022-2027)
  • Table 224. Rapid Adenovirus Testing Chromatography , by Region USD Million (2022-2027)
  • Table 225. Rapid Adenovirus Testing Gel Microdroplets , by Region USD Million (2022-2027)
  • Table 226. South America Rapid Adenovirus Testing, by Country USD Million (2022-2027)
  • Table 227. South America Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 228. South America Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 229. South America Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 230. Brazil Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 231. Brazil Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 232. Brazil Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 233. Argentina Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 234. Argentina Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 235. Argentina Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 236. Rest of South America Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 237. Rest of South America Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 238. Rest of South America Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 239. Asia Pacific Rapid Adenovirus Testing, by Country USD Million (2022-2027)
  • Table 240. Asia Pacific Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 241. Asia Pacific Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 242. Asia Pacific Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 243. China Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 244. China Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 245. China Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 246. Japan Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 247. Japan Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 248. Japan Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 249. India Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 250. India Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 251. India Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 252. South Korea Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 253. South Korea Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 254. South Korea Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 255. Taiwan Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 256. Taiwan Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 257. Taiwan Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 258. Australia Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 259. Australia Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 260. Australia Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 261. Rest of Asia-Pacific Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 262. Rest of Asia-Pacific Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 263. Rest of Asia-Pacific Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 264. Europe Rapid Adenovirus Testing, by Country USD Million (2022-2027)
  • Table 265. Europe Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 266. Europe Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 267. Europe Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 268. Germany Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 269. Germany Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 270. Germany Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 271. France Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 272. France Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 273. France Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 274. Italy Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 275. Italy Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 276. Italy Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 277. United Kingdom Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 278. United Kingdom Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 279. United Kingdom Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 280. Netherlands Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 281. Netherlands Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 282. Netherlands Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 283. Rest of Europe Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 284. Rest of Europe Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 285. Rest of Europe Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 286. MEA Rapid Adenovirus Testing, by Country USD Million (2022-2027)
  • Table 287. MEA Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 288. MEA Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 289. MEA Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 290. Middle East Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 291. Middle East Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 292. Middle East Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 293. Africa Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 294. Africa Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 295. Africa Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 296. North America Rapid Adenovirus Testing, by Country USD Million (2022-2027)
  • Table 297. North America Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 298. North America Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 299. North America Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 300. United States Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 301. United States Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 302. United States Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 303. Canada Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 304. Canada Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 305. Canada Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 306. Mexico Rapid Adenovirus Testing, by Application USD Million (2022-2027)
  • Table 307. Mexico Rapid Adenovirus Testing, by Assay USD Million (2022-2027)
  • Table 308. Mexico Rapid Adenovirus Testing, by Diagnosis USD Million (2022-2027)
  • Table 309. Rapid Adenovirus Testing Sales: by Application(K Units)
  • Table 310. Rapid Adenovirus Testing Sales Hospitals , by Region K Units (2022-2027)
  • Table 311. Rapid Adenovirus Testing Sales Clinics , by Region K Units (2022-2027)
  • Table 312. Rapid Adenovirus Testing Sales Others , by Region K Units (2022-2027)
  • Table 313. Rapid Adenovirus Testing Sales: by Assay(K Units)
  • Table 314. Rapid Adenovirus Testing Sales Lateral Flow Immunochromatographic Assay , by Region K Units (2022-2027)
  • Table 315. Rapid Adenovirus Testing Sales Immunogold Assay , by Region K Units (2022-2027)
  • Table 316. Rapid Adenovirus Testing Sales PCR-Enzyme Hybridization Assay , by Region K Units (2022-2027)
  • Table 317. Rapid Adenovirus Testing Sales: by Diagnosis(K Units)
  • Table 318. Rapid Adenovirus Testing Sales Antigen Detection , by Region K Units (2022-2027)
  • Table 319. Rapid Adenovirus Testing Sales Polymerase Chain Reaction (PCR) , by Region K Units (2022-2027)
  • Table 320. Rapid Adenovirus Testing Sales Virus Isolation , by Region K Units (2022-2027)
  • Table 321. Rapid Adenovirus Testing Sales Monoclonal Antibodies , by Region K Units (2022-2027)
  • Table 322. Rapid Adenovirus Testing Sales Liposomes and Flow Cytometry , by Region K Units (2022-2027)
  • Table 323. Rapid Adenovirus Testing Sales Chromatography , by Region K Units (2022-2027)
  • Table 324. Rapid Adenovirus Testing Sales Gel Microdroplets , by Region K Units (2022-2027)
  • Table 325. South America Rapid Adenovirus Testing Sales, by Country K Units (2022-2027)
  • Table 326. South America Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 327. South America Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 328. South America Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 329. Brazil Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 330. Brazil Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 331. Brazil Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 332. Argentina Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 333. Argentina Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 334. Argentina Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 335. Rest of South America Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 336. Rest of South America Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 337. Rest of South America Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 338. Asia Pacific Rapid Adenovirus Testing Sales, by Country K Units (2022-2027)
  • Table 339. Asia Pacific Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 340. Asia Pacific Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 341. Asia Pacific Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 342. China Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 343. China Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 344. China Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 345. Japan Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 346. Japan Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 347. Japan Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 348. India Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 349. India Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 350. India Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 351. South Korea Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 352. South Korea Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 353. South Korea Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 354. Taiwan Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 355. Taiwan Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 356. Taiwan Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 357. Australia Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 358. Australia Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 359. Australia Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 360. Rest of Asia-Pacific Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 361. Rest of Asia-Pacific Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 362. Rest of Asia-Pacific Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 363. Europe Rapid Adenovirus Testing Sales, by Country K Units (2022-2027)
  • Table 364. Europe Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 365. Europe Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 366. Europe Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 367. Germany Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 368. Germany Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 369. Germany Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 370. France Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 371. France Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 372. France Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 373. Italy Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 374. Italy Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 375. Italy Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 376. United Kingdom Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 377. United Kingdom Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 378. United Kingdom Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 379. Netherlands Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 380. Netherlands Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 381. Netherlands Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 382. Rest of Europe Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 383. Rest of Europe Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 384. Rest of Europe Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 385. MEA Rapid Adenovirus Testing Sales, by Country K Units (2022-2027)
  • Table 386. MEA Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 387. MEA Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 388. MEA Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 389. Middle East Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 390. Middle East Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 391. Middle East Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 392. Africa Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 393. Africa Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 394. Africa Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 395. North America Rapid Adenovirus Testing Sales, by Country K Units (2022-2027)
  • Table 396. North America Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 397. North America Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 398. North America Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 399. United States Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 400. United States Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 401. United States Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 402. Canada Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 403. Canada Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 404. Canada Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 405. Mexico Rapid Adenovirus Testing Sales, by Application K Units (2022-2027)
  • Table 406. Mexico Rapid Adenovirus Testing Sales, by Assay K Units (2022-2027)
  • Table 407. Mexico Rapid Adenovirus Testing Sales, by Diagnosis K Units (2022-2027)
  • Table 408. Research Programs/Design for This Report
  • Table 409. Key Data Information from Secondary Sources
  • Table 410. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rapid Adenovirus Testing: by Application USD Million (2016-2021)
  • Figure 5. Global Rapid Adenovirus Testing: by Assay USD Million (2016-2021)
  • Figure 6. Global Rapid Adenovirus Testing: by Diagnosis USD Million (2016-2021)
  • Figure 7. South America Rapid Adenovirus Testing Share (%), by Country
  • Figure 8. Asia Pacific Rapid Adenovirus Testing Share (%), by Country
  • Figure 9. Europe Rapid Adenovirus Testing Share (%), by Country
  • Figure 10. MEA Rapid Adenovirus Testing Share (%), by Country
  • Figure 11. North America Rapid Adenovirus Testing Share (%), by Country
  • Figure 12. Global Rapid Adenovirus Testing: by Application K Units (2016-2021)
  • Figure 13. Global Rapid Adenovirus Testing: by Assay K Units (2016-2021)
  • Figure 14. Global Rapid Adenovirus Testing: by Diagnosis K Units (2016-2021)
  • Figure 15. South America Rapid Adenovirus Testing Share (%), by Country
  • Figure 16. Asia Pacific Rapid Adenovirus Testing Share (%), by Country
  • Figure 17. Europe Rapid Adenovirus Testing Share (%), by Country
  • Figure 18. MEA Rapid Adenovirus Testing Share (%), by Country
  • Figure 19. North America Rapid Adenovirus Testing Share (%), by Country
  • Figure 20. Global Rapid Adenovirus Testing share by Players 2021 (%)
  • Figure 21. Global Rapid Adenovirus Testing share by Players (Top 3) 2021(%)
  • Figure 22. Global Rapid Adenovirus Testing share by Players (Top 5) 2021(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Biopanda Reagents Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Biopanda Reagents Ltd (United Kingdom) Revenue: by Geography 2021
  • Figure 26. CTK Biotech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. CTK Biotech Inc. (United States) Revenue: by Geography 2021
  • Figure 28. Creative Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Creative Diagnostics (United States) Revenue: by Geography 2021
  • Figure 30. Intec Products Inc. (China) Revenue, Net Income and Gross profit
  • Figure 31. Intec Products Inc. (China) Revenue: by Geography 2021
  • Figure 32. Biomérieux India Private Limited Revenue, Net Income and Gross profit
  • Figure 33. Biomérieux India Private Limited Revenue: by Geography 2021
  • Figure 34. Accuquik (United States) Revenue, Net Income and Gross profit
  • Figure 35. Accuquik (United States) Revenue: by Geography 2021
  • Figure 36. SA Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 37. SA Scientific (United States) Revenue: by Geography 2021
  • Figure 38. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 40. Diasorin S.P.A (Italy) Revenue, Net Income and Gross profit
  • Figure 41. Diasorin S.P.A (Italy) Revenue: by Geography 2021
  • Figure 42. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2021
  • Figure 44. Qiagen (Switzerland) Revenue, Net Income and Gross profit
  • Figure 45. Qiagen (Switzerland) Revenue: by Geography 2021
  • Figure 46. Global Rapid Adenovirus Testing: by Application USD Million (2022-2027)
  • Figure 47. Global Rapid Adenovirus Testing: by Assay USD Million (2022-2027)
  • Figure 48. Global Rapid Adenovirus Testing: by Diagnosis USD Million (2022-2027)
  • Figure 49. South America Rapid Adenovirus Testing Share (%), by Country
  • Figure 50. Asia Pacific Rapid Adenovirus Testing Share (%), by Country
  • Figure 51. Europe Rapid Adenovirus Testing Share (%), by Country
  • Figure 52. MEA Rapid Adenovirus Testing Share (%), by Country
  • Figure 53. North America Rapid Adenovirus Testing Share (%), by Country
  • Figure 54. Global Rapid Adenovirus Testing: by Application K Units (2022-2027)
  • Figure 55. Global Rapid Adenovirus Testing: by Assay K Units (2022-2027)
  • Figure 56. Global Rapid Adenovirus Testing: by Diagnosis K Units (2022-2027)
  • Figure 57. South America Rapid Adenovirus Testing Share (%), by Country
  • Figure 58. Asia Pacific Rapid Adenovirus Testing Share (%), by Country
  • Figure 59. Europe Rapid Adenovirus Testing Share (%), by Country
  • Figure 60. MEA Rapid Adenovirus Testing Share (%), by Country
  • Figure 61. North America Rapid Adenovirus Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Biopanda Reagents Ltd (United Kingdom)
  • CTK Biotech Inc. (United States)
  • Creative Diagnostics (United States)
  • Intec Products Inc. (China)
  • Biomérieux India Private Limited
  • Accuquik (United States)
  • SA Scientific (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Diasorin S.P.A (Italy)
  • Bio-Rad Laboratories Inc. (United States)
  • Qiagen (Switzerland)
Select User Access Type

Key Highlights of Report


Jul 2022 162 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Rapid Adenovirus Testing Market Quantitative research analysis
Global Rapid Adenovirus Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Biopanda Reagents Ltd (United Kingdom), CTK Biotech Inc. (United States), Creative Diagnostics (United States), Intec Products Inc. (China), Biomérieux India Private Limited, Accuquik (United States), SA Scientific (United States), F. Hoffmann-La Roche Ltd (Switzerland), Diasorin S.P.A (Italy), Bio-Rad Laboratories Inc. (United States) and Qiagen (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancement of Different PCR Methods" is seen as one of major influencing trends for Rapid Adenovirus Testing Market during projected period 2021-2027.
The Rapid Adenovirus Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Rapid Adenovirus Testing Market Report?

Have a Query? Click Here

Other Related Reports

Iron Deficiency Anemia Treatment Comprehensive Study by Application (Inflammatory Bowel Disease, Chronic Kidney Disease, Dialysis, Chronic Heart Failure, Women’s Health, Celiac Disease, Others {Cance...
$ 3750
Porphyrin Testing Comprehensive Study by Type (Test Kits, Reagent, Instruments), Application (Hospital Labs, Diagnostic Labs, Others), Sales Channels (Online {Company websites, e-commerce sites}, Off...
$ 3650
Aesthetic Fillers Comprehensive Study by Application (Face Lift, Facial Line Correction, Lip Treatment, Others), Material (Polymers and Particles, Hyaluronic Acid, Collagen) Players and Region - Glob...
$ 3500
Orosomucoid Glycoprotein Testing Comprehensive Study by Type (Elisa Kits, Instruments), Sales Channels (Online (Company Websites, E-Commerce Sites), Offline (Medical Stores, Suppliers, Distributors, ...
$ 3650
Virtual Health Comprehensive Study by Type (Telehealth {Telemedicine, Store and Forward, and Remote Patient Monitoring}, Digital Therapeutics {Replacement Therapies, and Treatment Optimization}, Care...
$ 3750
Surrogacy Service Comprehensive Study by Type (Traditional Surrogacy, Gestational Surrogacy), Application (Hospital, Fertility Clinic, Others), End Users (Intended Parents, Same-Sex Couples) Players ...
$ 3400